Since then, review studies have found that overall rates of congenital malformations in infants exposed to lamotrigine "in utero" are relatively low (1-4%).
Their use in the first trimester is also associated with a risk of major congenital malformations, particularly affecting the cardiovascular and central nervous systems.
